All In Biotech

Drug Trial Radar · NCT06361199

Proximod Pharmacokinetics in Healthy Subjects and Patients With Rheumatoid Arthritis

A Single-center, Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Proximod in Healthy Subjects and Patients With Rheumatoid Arthritis.

Last checked: Nov 19, 2026Latest source record: Apr 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Dec 16, 2021

Primary completion

Feb 16, 2022

Study completion Oct 8, 2023

Sponsor

Lead sponsor
Longevity Inc.Industry
Sponsor type
Industry
First posted
Apr 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects and patients with rheumatoid arthritis. The main questions it arms to answer are: 1. to evaluate the safety and tolerance of Proximod in health subjects after repeated doses. 2. to assess the pharmacokinetics and pharmacodynamics of Proximod in healthy subjects after repeated doses. 3. to evaluate the safety and tolerance of Proximod in patients with rheumatoid arthritis. 4. to evaluate the pharmacokinetics and pharmacodynamics of Proximod in patients with rheumatoid arthritis. Participants will receive test tablets or placebo at the indicated date and collect blood samples.

Conditions

  • Rheumatoid Arthritis

Interventions

  • ProximodDrug

    Multiple-dose to establish the safety and PK profile in both healthy subjects and patients with rheumatoid arthritis

  • PlaceboDrug

    Placebo controlled

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak plasma concentration (Cmax)Time frame: Up to 48 days
  2. Time to peak plasma concentration (Tmax)Time frame: Up to 48 days
  3. The lowest plasma concentration (Cmin)Time frame: Up to 48 days
  4. Half-life (t1/2)Time frame: Up to 48 days
  5. Area under the plasma concentration versus time curve (AUC)Time frame: Up to 48 days
  6. Number of adverse events and number of participants with adverse eventsTime frame: Up to 48 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The first hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.